CoChat

Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study

Open access
Holz, Frank G, Tadayoni, Ramin, Beatty, Stephen, Berger, Alan, Cereda, Matteo Giuseppe, Hykin, Philip, Staurenghi, Giovanni, Wittrup-Jensen, Kim, Altemark, Andreas, Nilsson, Jonas, Kim, Kun, Sivaprasad, Sobha · 2016 · British Journal of Ophthalmology
Cited by 124

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

BACKGROUND/AIMS: To identify predictive markers for the outcomes of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration (nAMD). METHODS: AURA was a retrospective, observational, multicentre study that monitored the 2-year outcomes following intravitreal ranibizumab treatment in patients with nAMD. Using stepwise regression analysis, we evaluated the association between visual acuity outcomes, baseline characteristics and resource utilisation in order to determine which variables are significantly linked to outcomes in AURA. We also examined the relationship between visual acuity outcomes and number of injections received. RESULTS: Analyses were performed using data from year 1 (n=1695) and year 2 completers (n=1184). Logistic analysis showed that baseline visual acuity score, age at start of therapy, number of ophthalmoscopies and optical coherence tomography (OCT) (combined) and number of injections (ranibizumab) were significant (p<0.05) prognostic factors for vision maintenance (loss <15 letters) or vision gain (≥15 letters). Patients who received >7 injections (in 1 year) or >14 injections (over 2 years) gained more letters and demonstrated greater vision maintenance (loss of <15 letters) than patients who received fewer injections. There was a significant (p<0.05) association between number of injections and national reimbursement schemes and OCT. CONCLUSIONS: A number of factors that are predictive of treatment outcomes in a real-life setting were identified. Notably, the decline of treatment benefits may be linked to number of injections and a failure to visit clinicians and receive OCT as required. These findings may be helpful in guiding ophthalmologist treatment decisions under limited time and financial constraints. TRIAL REGISTRATION NUMBER: NCT01447043.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bjophthalmol-2015-308166

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 124

Metadata

Authors
Holz, F. G., Tadayoni, R., Beatty, S., Berger, A., Cereda, M. G., Hykin, P., Staurenghi, G., Wittrup-Jensen, K., Altemark, A., Nilsson, J., Kim, K., & Sivaprasad, S.
Venue
British Journal of Ophthalmology
Publisher
BMJ
Published
2016-03-30
Volume
100
Issue
12
Pages
1623-1628
ISSN
  • 0007-1161 (ISSN-L)
  • 1468-2079
OpenAlex
W2319705424
Cited by
124
References
9
FWCI
14.62
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. https://app.cochat.ai/papers/10.1136/bjophthalmol-2015-308166
The paper
Holz, F. G., Tadayoni, R., Beatty, S., Berger, A., Cereda, M. G., Hykin, P., Staurenghi, G., Wittrup-Jensen, K., Altemark, A., Nilsson, J., Kim, K., & Sivaprasad, S. (2016). Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2015-308166

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.